IL6 and metabolic syndrome: Leucker et al. [59] reported that unchanged inflammatory biomarkers, including high-sensitivity, C-reactive protein, IL-6, interferon-gamma, tumour necrosis factor-alpha, and soluble CD163 were unchanged in dyslipidemia patients treated with evolocumab.